AbbVie : ABBV

All AbbVie Articles

612 Articles

Vandita Jadeja | May 6, 2026 at 10:32 AM EDT

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest…

Vandita Jadeja | May 4, 2026 at 8:55 AM EDT

10 Years, Zero Regrets: The Dividend Stocks I Keep Buying

Dividend stocks can be a pillar for long-term investing, generating passive income and offering stability even during tough environments. The…

Vandita Jadeja | Apr 30, 2026 at 10:40 AM EDT

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Our AbbVie (NYSE:ABBV | ABBV Price Prediction) call lands on the constructive side of the ledger after a noisy but…

Lee Jackson | Apr 30, 2026 at 7:49 AM EDT

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading session that saw all major indices…

John Seetoo | Apr 25, 2026 at 6:35 AM EDT

Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital

Income investors shopping the healthcare aisle often land on Gabelli Healthcare & WellnessRx Trust (NYSE:GRX), a closed-end fund managed by…

Vandita Jadeja | Apr 23, 2026 at 4:04 PM EDT

These 5 Stocks Pay You Even When You’re Sleeping

Market volatility in 2026 has reminded investors that earned income alone is fragile. When tariff fears rattle equities and economic…

David Beren | Apr 21, 2026 at 3:34 PM EDT

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

Gabelli Dividend & Income Trust (NYSE:GDV) trades near $29 and pays a $0.15 monthly distribution, up from $0.11 per month…

David Moadel | Apr 21, 2026 at 10:30 AM EDT

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

One of Wall Street’s top firms just made the bull case for AbbVie (NYSE:ABBV | ABBV Price Prediction) stock, initiating…

Vandita Jadeja | Apr 20, 2026 at 10:37 AM EDT

Why I Can’t Stop Buying AbbVie Stock

AbbVie (NYSE:ABBV | ABBV Price Prediction) has attracted persistent buying interest, and every pullback has drawn in value-focused investors. The…

Vandita Jadeja | Apr 17, 2026 at 10:22 AM EDT

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record…

David Moadel | Apr 7, 2026 at 9:58 AM EDT

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

AbbVie (NYSE:ABBV | ABBV Price Prediction) stock has pulled back 12% over the past month, sliding to around $204. JPMorgan…

Vandita Jadeja | Apr 6, 2026 at 12:15 PM EDT

High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout

Pharmaceutical companies AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, revealing two…

Lee Jackson | Apr 2, 2026 at 8:10 AM EDT

The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income

With inflation back in the economic picture, simply getting a dependable income stream may not be the best strategy for…

John Seetoo | Mar 27, 2026 at 11:49 AM EDT

Why Income Investors Keep VTV as a Core Portfolio Anchor in a Turbulent 2026

Retirees and income-focused investors have long used Vanguard Value ETF (NYSEARCA:VTV) as a core portfolio anchor, drawn to its dividend…

Michael Williams | Mar 26, 2026 at 2:32 PM EDT

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Healthcare spending doesn’t stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT),…

1 2 3 4 5 6 … 41

AbbVie : ABBV

All AbbVie Articles

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

10 Years, Zero Regrets: The Dividend Stocks I Keep Buying

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital

These 5 Stocks Pay You Even When You’re Sleeping

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

Why I Can’t Stop Buying AbbVie Stock

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout

The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income

Why Income Investors Keep VTV as a Core Portfolio Anchor in a Turbulent 2026

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

What It Takes to Age in Place, And the Portfolio That Pays For It

He Retired at 55 With $1.2 Million in His 401(k). One Routine Paperwork Move Would Have Locked It All Up for Years

Have a Big 401(k) and Turning 60? Your Catch-Up Limit Just Jumped to $11,250 and the Window Closes at 64

What It Takes to Age in Place, And the Portfolio That Pays For It

He Retired at 55 With $1.2 Million in His 401(k). One Routine Paperwork Move Would Have Locked It All Up for Years

What It Takes to Age in Place, And the Portfolio That Pays For It

He Retired at 55 With $1.2 Million in His 401(k). One Routine Paperwork Move Would Have Locked It All Up for Years

AbbVie : ABBV

All AbbVie Articles

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

10 Years, Zero Regrets: The Dividend Stocks I Keep Buying

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Healthcare CEF Insiders Are Quietly Buying While 60% of Distributions Return Capital

These 5 Stocks Pay You Even When You’re Sleeping

GDV’s 6.1% Yield Faces a Hidden Test in 2026 Small-Cap Downturn

Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

Why I Can’t Stop Buying AbbVie Stock

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit

AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns

High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout

The 5 Safest Dividend Aristocrats Are Perfect For Retirees Needing Growth & Income

Why Income Investors Keep VTV as a Core Portfolio Anchor in a Turbulent 2026

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

What It Takes to Age in Place, And the Portfolio That Pays For It

He Retired at 55 With $1.2 Million in His 401(k). One Routine Paperwork Move Would Have Locked It All Up for Years

Have a Big 401(k) and Turning 60? Your Catch-Up Limit Just Jumped to $11,250 and the Window Closes at 64

Featured Reads

What It Takes to Age in Place, And the Portfolio That Pays For It

He Retired at 55 With $1.2 Million in His 401(k). One Routine Paperwork Move Would Have Locked It All Up for Years